FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 647 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR The HPV Vaccine: Increasing the Use of an Important Cancer Prevention... December 20, 2018 TRACERx EVO, a new programme to transform lung cancer research November 9, 2022 Spirituality Resources December 9, 2020 Reflections May 26, 2021 Load more HOT NEWS Study Shows That Fast-Mimicking Diets Are Safe and Effective for Patients... No EFS Benefit From Adding Atezolizumab To 1-Year BCG Therapy In... En gran cantidad de casos el exito o examen experto os... NEOSTAR Results Indicate that Neoadjuvant Nivolumab Plus Ipilimumab Enhances Pathologic Responses...
